176 related articles for article (PubMed ID: 26331989)
1. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
3. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
4. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Bae J; Park JW
Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
[TBL] [Abstract][Full Text] [Related]
5. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
7. The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
Hopkins AM; O'Doherty CE; Foster DJ; Suppiah V; Upton RN; Spargo LD; Cleland LG; Proudman SM; Wiese MD
J Clin Pharm Ther; 2014 Oct; 39(5):555-60. PubMed ID: 25040563
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Bergner R; Peters L; Schmitt V; Löffler C
Clin Rheumatol; 2013 Feb; 32(2):267-70. PubMed ID: 23179005
[TBL] [Abstract][Full Text] [Related]
11. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
Yao X; Wu Y; Jiang J; Hu P; Liu D; Chen X
Clin Drug Investig; 2019 Jul; 39(7):643-651. PubMed ID: 31016613
[TBL] [Abstract][Full Text] [Related]
12. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
Rule GS; Rockwood AL; Johnson-Davis KL
Methods Mol Biol; 2019; 1872():75-83. PubMed ID: 30350281
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
Rawdha T; Aicha BT; Lobna BA; Issam S; Mouna BS; Olfa S; Selma B; Takoua BB; Kawther BA; Leila M; Hana S; Ines M; Leila A
Drug Metab Pers Ther; 2023 Mar; 38(1):79-85. PubMed ID: 35998916
[TBL] [Abstract][Full Text] [Related]
15. On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
Kujawski J; Bernard MK; Jodłowska E; Czaja K; Drabińska B
J Mol Model; 2015 May; 21(5):105. PubMed ID: 25851105
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide.
Song Y; Zhang Y; Lee AR; Huang WH; Chen B; Palfey B; Shaw J
Curr Pharm Des; 2014; 20(1):146-52. PubMed ID: 23944378
[TBL] [Abstract][Full Text] [Related]
17. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
18. Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Foster D; Upton RN
CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):362-71. PubMed ID: 26225264
[TBL] [Abstract][Full Text] [Related]
19. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide.
Yao X; Liu Y; Song L; Jiang J; Xiao F; Liu D; Hu P
Biomed Chromatogr; 2019 Mar; 33(3):e4420. PubMed ID: 30362147
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]